Bayer Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Healthcare LLC

Bayer Pharma Aktiengesellschaft

Michael Lögers

Hilmar Bischoff

Delf Schmidt

Gunter Schmidt

Arndt Brandes

Carsten Schmeck

Rolf Angerbauer

Klaus-Dieter Bremm

Matthias Muller-Gliemann

Werner Heilmann

Joachim Schuhmacher

Joachim Rehse

Michael Gottfried

Jürgen Stoltefuss

Juergen Stiehl

Saskia Wichmann

Stefan Wohlfeil

Reinhold Gehring

Martin Bechem

Jurgen Stoltefuss

Klemens Lustig

Christoph Gerdes

Paul Naab

Michael Sperzel

Klaus Mohrs

Holger Paulsen

Henry Giera

Mathias Berwe

Oliver Kuhn

Ulrich Nielsch

Michael Conrad

Jana Lenz

Werner Stürmer

Mike Matthäus

Jürgen Stiehl

Matthias Müller-Gliemann

Gabriele Bräunlich

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-N-methylpyridine-2-carboxamide, its salts and monohydrate.

Process for the preparation of 4-(4-amino-3-fluorophenoxy)-N-methylpyyridine-2-carboxamide

The present invention relates to a process for preparing 4-(4-[({[4-chloro-3-(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy)-N-methylpyridine-2-carboxamide, its salts and monohydrate.

[object Object]

The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoro-methyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide and its tosylate salt.

Process for the preparation of 4-{4-[({[4 chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide

Hetero-tetrahydroquinolines can be prepared either by condensing correspondingly substituted hetero-tetrahydroquinoline aldehydes with the desired substituent or by reducing the corresponding keto-substituted hetero-tetrahydroquinolines, followed by introduction of the desired substituent by customary methods. The hetero-tetrahydroquinolines are suitable for use as active compounds in medicaments, in particular in medicaments for treating artheriosclerosis and dyslipidaemias.

4-heteroaryl-tetrahydroquinolines and their use as inhibitors of the cholesterin-ester transfer protein

The tetrahydroquinolines can be prepared by condensing appropriately substituted tetrahydroquinoline aldehydes with suitable substances and subsequently varying the substituents present by customary methods. The tetrahydroquinolines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis and dyslipidaemias.

4-Phenyltetrahydrochinoline utilized as an inhibitor of the cholesterol ester transfer protein

A process is provided for preparing 3,6-dihydro-2H-pyran-2-carboxylic esters via a thermal hetero Diels-Alder reaction of 1,3-dienes with glyoxylic esters without the use of catalysts and stabilizers using a special metering technique.

Preparation of 3,6-dihydro-2H-pyran-2-carboxylic esters

The present invention relates to 6-carboxyphenyldihydropyridazinone derivatives having the formulawherein R, R, R, A, D, G, and E are as defined in the specification and claims, a process for preparing these materials, pharmaceutical compositions containing them, and a method for using them in the treatment of anemias.

6-carboxyphenyldihydropyridazinone derivatives and use thereof

The 2-aryl-substituted pyridines are prepared by reacting pyridylaldehydes with organometallic compounds and then selectively reducing the products. The 2-aryl-substituted pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosis.

2-aryl-substituted pyridines

5-Hydroxyalkyl substituted phenyls and their use in medicaments for the

The cycloalkano-pyridines are prepared by reacting corresponding cycloalkano-pyridine-aldehydes with suitable organometallic compounds or Wittig or Grignard reagents or reacting compounds of the cycloalkano-pyridine alcohols type with suitable bromine compounds, and optionally varying the functional groups accordingly. The, cycloalkanopyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of hyperlipoproteinaemia and arteriosclerosis.

Cycloalkano-pyridines

Bicyclic-fused pyridines are prepared by introducing the appropriate side chain by reaction of the corresponding aldehydes with the aid of Wittig or Grignard reagents. The bicyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of arteriosclerosi.

Bicyclic-fused pyridines

The heterocyclic-fused pyridines are prepared by reaction of the corresponding heterocyclic-fused pyridine aldehydes with appropriately substituted Grignard or Wittig reagents. The heterocyclic-fused pyridines are suitable as active compounds in medicaments, in particular in medicaments for the treatment of dislipidaemia and arteriosclerosis.

Heterocyclic-fused pyridines

Growing community of inventors

Wuppertal, Germany

Michael Lögers